Current Rating and Its Significance
MarketsMOJO currently assigns Sunil Healthcare Ltd a 'Sell' rating, indicating a cautious stance towards the stock. This rating suggests that investors should consider reducing exposure or avoiding new purchases, given the company’s present financial and market conditions. The rating was last revised on 01 Apr 2026, when the Mojo Score improved from 29 to 37 points, moving the grade from 'Strong Sell' to 'Sell'. Despite this improvement, the overall outlook remains negative, reflecting ongoing challenges in the company’s performance and market sentiment.
Here’s How the Stock Looks Today
As of 18 May 2026, Sunil Healthcare Ltd remains a microcap player in the Pharmaceuticals & Biotechnology sector, with a Mojo Score of 37.0 and a 'Sell' grade. The stock has shown mixed price movements recently, with a 1-day gain of 1.24%, a 1-week rise of 3.37%, and a modest 1-month increase of 0.61%. However, longer-term returns paint a less favourable picture: the stock has declined by 2.01% over three months, 9.28% over six months, 11.25% year-to-date, and 24.60% over the past year.
Quality Assessment
The quality grade for Sunil Healthcare Ltd is below average, reflecting fundamental weaknesses. The company’s long-term fundamental strength is weak, with an average Return on Capital Employed (ROCE) of just 5.21%. This indicates limited efficiency in generating profits from its capital base. Additionally, net sales have grown at a sluggish annual rate of 1.43% over the last five years, signalling minimal top-line expansion. The company’s ability to service debt is also a concern, with a high Debt to EBITDA ratio of 4.64 times, suggesting elevated leverage and potential financial risk.
Valuation Perspective
Despite the challenges in quality, the valuation grade is very attractive. This suggests that the stock is trading at a price that may offer value relative to its earnings, assets, or cash flows. For value-oriented investors, this could present an opportunity to acquire shares at a discount to intrinsic worth. However, the attractive valuation must be weighed against the company’s operational and financial risks before making investment decisions.
Financial Trend Analysis
The financial grade is positive, indicating some favourable trends in the company’s recent financial performance. While growth has been limited, the company appears to maintain a stable financial footing in the short term. This positive trend may reflect improvements in profitability, cash flow generation, or cost management, which could support a turnaround if sustained. Nonetheless, the overall weak fundamentals temper enthusiasm for the stock.
Technical Outlook
Technically, the stock is mildly bearish. This suggests that price momentum and chart patterns currently favour a downward or cautious trend. Investors relying on technical analysis might interpret this as a signal to avoid initiating new positions or to consider exiting existing holdings until clearer signs of recovery emerge.
Performance Relative to Benchmarks
Sunil Healthcare Ltd has consistently underperformed the broader market benchmark BSE500 over the past three years. The stock’s returns have lagged significantly, with a 1-year return of -24.60% compared to the benchmark’s positive performance. This persistent underperformance highlights the challenges the company faces in delivering shareholder value relative to its peers and the wider market.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
What This Rating Means for Investors
For investors, the 'Sell' rating on Sunil Healthcare Ltd serves as a cautionary signal. It reflects a combination of below-average quality, attractive valuation, positive financial trends, and a mildly bearish technical outlook. While the valuation may tempt value investors, the company’s weak fundamentals and persistent underperformance suggest that risks remain elevated. Investors should carefully consider their risk tolerance and investment horizon before committing capital to this stock.
Summary of Key Metrics as of 18 May 2026
To summarise, the stock’s key metrics as of today include:
- Mojo Score: 37.0 (Sell grade)
- Return on Capital Employed (ROCE): 5.21%
- Net Sales Growth (5-year CAGR): 1.43%
- Debt to EBITDA Ratio: 4.64 times
- Stock Returns: 1D +1.24%, 1W +3.37%, 1M +0.61%, 3M -2.01%, 6M -9.28%, YTD -11.25%, 1Y -24.60%
These figures highlight the stock’s current challenges and the rationale behind the 'Sell' rating. Investors should monitor future developments closely, including any improvements in operational efficiency, debt management, and market conditions that could alter the company’s outlook.
Sector Context
Operating within the Pharmaceuticals & Biotechnology sector, Sunil Healthcare Ltd faces intense competition and regulatory pressures. The sector often rewards companies with strong innovation pipelines and robust financial health. In this context, Sunil Healthcare’s below-average quality and weak growth metrics place it at a disadvantage compared to more dynamic peers. This sector backdrop further supports a cautious investment stance.
Conclusion
In conclusion, Sunil Healthcare Ltd’s 'Sell' rating by MarketsMOJO, last updated on 01 Apr 2026, reflects a comprehensive assessment of its current financial and market position as of 18 May 2026. While valuation appears attractive, the company’s weak fundamentals, financial leverage, and technical signals warrant prudence. Investors should weigh these factors carefully and consider alternative opportunities within the sector or broader market.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
